Hana Algül

Prof. Hana Algül is a Professor at the Technical University of Munich (TUM), leading the Chair of Tumor Metabolism within the TUM School of Medicine and Health. She holds a dual background in clinical medicine and scientific research, having earned degrees from the University of Ulm and the University of California Davis. Since 2003, she has served as a Clinician Scientist at TUM's Klinikum rechts der Isar, focusing on pancreatic cancer mechanisms and translational research. Her academic career includes key roles in clinical trials (e.g., NEONAX) and drug development.

Her research emphasizes tumor metabolism's role in pancreatic cancer progression, particularly autophagy regulation, immune-tumor interactions, and cachexia pathways. She investigates carcinogenesis triggers and immune modulation strategies, aiming to identify novel therapeutic targets. Notable contributions include studies on KRAS-driven cancers, biomarker discovery via imaging, and the impact of clinical trials during pandemics.

Prof. Algül’s work integrates preclinical models (mouse studies) with clinical data, addressing both molecular mechanisms and patient outcomes. Her team explores synergistic drug combinations (e.g., SHP2/ERK inhibition) and biomarkers for personalized treatment. She has published extensively on pancreatic cancer subtypes, metastasis pathways, and the effects of systemic therapies like olaparib in BRCA-mutated cancers.

• Education: MD from University of Ulm, Postdoctoral work at University of California Davis
• Labs/Teams: TUM Cancer Center, Klinikum rechts der Isar Research Group
• Key Projects: NEONAX trial (perioperative chemotherapy), POLO trial (olaparib maintenance), Hourglass subtyping framework